470. Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to Severe Immunocompromised (IC) Conditions across a Large U.S. Healthcare System: A Propensity Score-Matched Retrospective Cohort Study

BACKGROUND: T/C authorization in the US for PrEP of COVID-19 in IC individuals was initially based on a randomized trial (PROVENT). However, < 5% of enrollees in PROVENT were IC. We sought to assess real-world effectiveness of T/C PrEP among IC pts. METHODS: We conducted a retrospective, observat...

Descripción completa

Detalles Bibliográficos
Autores principales: Haidar, Ghady, Ludwig, Justin, Yealy, Donald M, Camacho, Haley, Chinakarn, Tina, Kip, Kevin, Koscumb, Stephen, Marroquin, Oscar, Minnier, Tami, Snyder, Graham M, Woodworth, Chelsea, Ferreira, Cátia, Glasser, Lisa, Heil, Kathleen, Lee, Andrew, Talarico, Carla, Venkatesan, Sudhir, Taylor, Sylvia, McCreary, Erin K, Mellors, John W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677105/
http://dx.doi.org/10.1093/ofid/ofad500.540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677105/
http://dx.doi.org/10.1093/ofid/ofad500.540

Ejemplares similares